Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02666248 · ClinicalTrials.gov registry record
Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 3
- Enrollment target
NCT02666248: Completed study, sponsored by University of Pennsylvania.
NCT02666248 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02666248 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received retroviral-based gene therapy products in cancer studies. All subjects in this LTFU protocol have received lentiviral modified T cells engineered to express an anti-EGFRvIII scFv Chimeric Antigen Receptor (CAR).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2018-01-27 |
What the finished NCT02666248 record still lists
NCT02666248 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02666248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02666248 about?
NCT02666248 is a clinical study titled "Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies". This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received retroviral-based gene therapy products in cancer studies. All subjects in this LTFU protocol have received lentiviral modified T cells engineered to express an anti-EGFRvIII scFv Chimeric Antigen Receptor (CAR)...
What is the current status of trial NCT02666248?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2016-05-23. Estimated completion is 2018-01-27.
Who is sponsoring clinical trial NCT02666248?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI